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A B S T R A C T
In the last decade it has been recapitulated that receptor-ligand binding kinetics is a relevant additional para-
meter in drug discovery to improve in vivo drug efficacy and safety. The equilibrative nucleoside transporter-1
(ENT1, SLC29A1) is an important drug target, as transporter inhibition is a potential treatment of ischemic heart
disease, stroke, and cancer. Currently, two non-selective ENT1 inhibitors (dilazep and dipyridamole) are on the
market as vasodilators. However, their binding kinetics are unknown; moreover, novel, more effective and se-
lective inhibitors are still needed. Hence, this study focused on the incorporation of binding kinetics for finding
new and improved ENT1 inhibitors.
We developed a radioligand competition association assay to determine the binding kinetics of ENT1 in-
hibitors with four chemical scaffolds (including dilazep and dipyridamole). The kinetic parameters were com-
pared to the affinities obtained from a radioligand displacement assay. Three of the scaffolds presented high
affinities with relatively fast dissociation kinetics, yielding short to moderate residence times (RTs) at the protein
(1–44 min). While compounds from the fourth scaffold, i.e. draflazine analogues, also had high affinity, they
displayed significantly longer RTs, with one analogue (4) having a RT of over 10 h. Finally, a label-free assay was
used to evaluate the impact of divergent ENT1 inhibitor binding kinetics in a functional assay. It was shown that
the potency of compound 4 increased with longer incubation times, which was not observed for draflazine,
supporting the importance of long RT for increased target-occupancy and effect.
In conclusion, our research shows that high affinity ENT1 inhibitors show a large variation in residence times
at this transport protein. As a consequence, incorporation of binding kinetic parameters adds to the design
criteria and may thus result in a different lead compound selection. Taken together, this kinetic approach could
inspire future drug discovery in the field of ENT1 and membrane transport proteins in general.
1. Introduction
Nucleoside Transporters (NTs) belong to the Solute Carrier (SLC)
family and are transmembrane proteins that act as the cell’s gatekeepers
for purine and pyrimidine nucleobases and nucleosides [1]. They play a
vital role in many cellular processes including protein synthesis, cell
replication, signal transduction, energy source and metabolism [2,3].
The NTs are classified into two major classes, sodium-dependent con-
centrative transporters (CNTs; SLC28) and equilibrative (ENTs; SLC29)
NTs.
Human ENT1 (hENT1; SLC29A1) is the best-studied SLC29 member
[4]. It is expressed throughout the human body in tissues such as gas-
trointestinal tract, vascular endothelium, brain, while its expression
levels vary between tissues [5,6]. ENT1 is known to have 11 trans-
membrane (TM) domains, and the region between TM domains 3 and 6
is responsible for the binding of reference inhibitors, such as dilazep,
and S-(4-Nitrobenzyl)-6-thioinosine (NBTI), which was recently con-
firmed by the first crystal structure of this protein [7].
ENT1 has been extensively studied as a target for nucleoside ana-
logue drugs, which are transported inside the cell, and used in the
treatment of cancer or viral infections. Examples are gemcitabine [8],
and ribavirin [9]. However, inhibition of ENT1 has also been proven to
be a promising therapeutic strategy. Adenosine is a purine nucleoside
and the main substrate of ENT1, as well as the endogenous ligand of a G
protein-coupled receptor (GPCR) subfamily, the adenosine receptors
(i.e. A1, A2A, A2B and A3). Inhibition of ENT1 modulates the extra-
cellular concentration of adenosine leading to increased signaling via
adenosine receptors, hence to a therapeutic effect. For example, dra-
flazine has been shown to protect heart tissue against ischemia-induced
damage, and its effect was attributed to the increased extracellular
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adenosine concentration [10]. Dilazep and dipyridamole, the two
marketed ENT1 inhibitors, act as vasodilators via the same mechanism,
however their effect is enhanced by inhibiting other targets, as they are
non-selective [11,12].
In the last two decades target binding kinetics has emerged as an
important parameter in drug discovery. Since then a plethora of re-
search on association, and dissociation rate constants, kon and koff, re-
spectively, has shown that in vivo efficacy is often associated to opti-
mized binding kinetic parameters of the ligand [13,14]. Association
rate has been found essential for high target occupancy, as it increases
rebinding to the target [15]. In addition, it has been proven important
for drug selectivity towards different targets, resulting to a higher drug
safety [16]. Concerning koff, its optimization leads to the tuning of
target residence time (RT) and as a result to a favorable duration of
action and efficacy [17]. Although the binding kinetics of some ENT1
inhibitors have been studied [18], they have yet to be incorporated in
drug discovery efforts, i.e. by constructing structure-kinetics (SKR) next
to structure-affinity relationships (SAR).
In this study, we report the biological evaluation of ENT1 reference
inhibitors from four chemical scaffolds, i.e. NBTI, dilazep, dipyridamole
and draflazine (Fig. 1), as well as of nine draflazine analogues. For the
purposes of this work [3H]NBTI binding was characterized and a
competition association assay was developed and validated for the
determination of inhibitor target binding kinetics. In addition, kineti-
cally diverse inhibitors were functionally evaluated in a label-free im-
pedance-based assay, where it was shown that divergent binding ki-
netics resulted in distinct functional inhibition. Taken together, we
established both structure-affinity and structure-kinetics relationships
(SAR and SKR) for ENT1 inhibitors, from which one of the draflazine
analogues emerged as an inhibitor with very slow dissociation rate and
a prolonged functional effect compared to the other inhibitors.
2. Methods and materials
2.1. Materials and reagent
NBTI was purchased from Sigma-Aldrich (St. Louis, MO, USA) and
dilazep was acquired from Asta-Werke (Degussa Pharma Gruppe,
Bielefeld, Germany). Dipyridamole was kindly provided by Boehringer
Ingelheim (Ingelheim, Germany), and draflazine and draflazine analo-
gues were kindly gifted by Janssen Pharmaceutics (Beerse, Belgium).
The radioligand [3H]-S-(4-Nitrobenzyl)-6-thioinosine ([3H]NBTI) with
a specific activity of 50 Ci × mmol−1 was purchased from PerkinElmer
(Groningen, The Netherlands). Bovine serum albumin (BSA) and the
bicinchoninic acid (BCA) protein assay kit were purchased from Fisher
Scientific (Hampton, New Hampshire, United States), while 3- [(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) was
obtained from Carl Roth GmbH (Karlsruhe, Germany). Erythrocytes
were obtained from Sanquin Bloedvoorziening (Amsterdam, the
Netherlands). Dulbecco’s modified Eagle’s medium (DMEM) and
Glutamax-1 were from Sigma Aldrich (St. Louis, MO, USA). Penicillin
and streptomycin, were obtained from Duchefa Biochemie (Haarlem,
The Netherlands). New Born Calf Serum (NBCS) was from Biowest
(Nuaillé, France). Homo sapiens bone osteosarcoma cells (U-2 OS) were
a kind gift from Mr. Hans den Dulk (Leiden Institute of Chemistry,
department of Molecular Physiology, Leiden University, the
Netherlands; originally obtained from and certified by American Type
Culture Collection (ATCC)). All other chemicals and materials were
obtained from standard commercial sources.
2.2. Cell culture
U-2 OS cells were cultured in DMEM supplemented with stable
glutamine, 10% (v/v) NBCS, 100 IU/ml penicillin and 100 mg/ml
streptomycin at 37 °C and 7% CO2. Cells were cultured as a monolayer
Fig. 1. Chemical structures of the four reference hENT1 inhibitors used in this study. Draflazine is the (−)-enantiomer and the asymmetric carbon atom is indicated
by *.
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on 10 cm ø plates and were subcultured twice every week at a ratio of
1:8. The cells were used for whole cell experiments when a confluency
of ~90% was reached.
2.3. Membrane preparation
Erythrocytes stored at 4 °C in saline-adenine-glucose-mannitol
(SAGM) were stirred in lysis buffer (10 mM MgCl2 in 10 mM Tris-HCl,
pH 8.0) (1/2 v/v) for 1 h at 25 °C and homogenized using an Ultra
Turrax homogenizer at 24,000 rpm (IKA-Werke GmbH & Co.KG,
Staufen, Germany). The homogenized sample was centrifuged at
8000 rpm (13,700 g) at 4 °C for 1 h in a Sorvall RC 6+ centrifuge
(Thermo Scientific). Pellets were resuspended in ice-cold milli-Q water
(Millipore S.A.S., Molsheim, France) homogenized and centrifuged at
37,500 rpm (150,000 g) at 4 °C for 20 min in an Optima LE-80K ul-
tracentrifuge (Beckman Coulter, Fullerton, CA). After resuspension of
pellets in ice-cold milli-Q water, the centrifugation and homogenization
steps were repeated till the supernatant was colorless. After the last
centrifugation step, pellet was resuspended in buffer (50 mM Tris-HCl,
pH 7.4 at 4 °C) and homogenized. Aliquots were prepared and stored at
−80 °C. Membrane protein concentrations were measured using the
BCA method [19].
2.4. Radioligand binding assay
In all experiments, erythrocyte membranes were thawed, homo-
genized using an Ultra Turrax homogenizer at 24,000 rpm (IKA-Werke
GmbH & Co.KG, Staufen, Germany) and diluted to the desired con-
centration (2 μg/well) using assay buffer (50 mM Tris-HCl pH 7.4, 0.1%
(w/v) CHAPS). Assay buffer, (radio)ligands and membranes were
cooled for 30 min at 10 °C prior to the experiment. Nonspecific binding
was determined in the presence of 10−5 M unlabeled NBTI. Total re-
action volume was 100 μL (except for wash-out experiments which was
400 μL) and dimethylsulfoxide (DMSO) final concentrations were
≤0.25%. In all cases total binding did not exceed 10% of the [3H]NBTI
added to the assay in order to prevent ligand depletion.
2.4.1. Equilibrium assays
Displacement experiments were carried out using [3H]NBTI (4 nM)
and a competing ligand at multiple concentrations. Binding was in-
itiated by addition of membranes, and samples were incubated at 10 °C
for 60 min to reach equilibrium. The incubation was terminated by
rapid vacuum filtration over 96-well Whatman GF/C filter plates using
a PerkinElmer Filtermate harvester (PerkinElmer, Groningen,
Netherlands). Filters were subsequently washed ten times using ice-cold
wash buffer (50 mM Tris-HCl, pH 7.4). Filter plates were dried at 55 °C
for about 45 min and afterwards 25 μL Microscint (PerkinElmer) was
added per well. Filter-bound radioactivity was determined by liquid
scintillation spectrometry using a 2450 Microbeta2 scintillation counter
(PerkinElmer).
Saturation binding experiments were carried out by incubating in-
creasing concentrations of [3H]NBTI (from 0.12 to 12 nM) with mem-
brane aliquots for 60 min at 10 °C. Incubation was terminated by fil-
tration and samples were obtained as described under “Displacement
experiments”.
2.4.2. Kinetic assays
Association experiments were performed by incubation of [3H]NBTI
(4 nM) with membrane aliquots at 10 °C. The amount of receptor-bound
radioligand was determined after filtration at different time intervals
for a total incubation time of 60 min and samples were obtained as
described under “Displacement experiments”.
Dissociation experiments were carried out by a 60 min pre-incubation
of radioligand [3H]NBTI (4 nM) and membrane aliquots. Subsequently,
dissociation of the radioligand at different time points up to 150 min
was initiated by addition of 5 µL NBTI (final concentration 10 µM).
Dissociation experiments were performed at 10 °C. The amount of re-
ceptor-bound radioligand was determined after filtration and samples
were obtained as described under “Displacement experiments”.
Competition association experiments were performed by incubation of
radioligand (4 nM) and competing ligand at its IC50 concentration (i.e.
determined in displacement experiments and displayed in the Table
below) with membrane aliquots at 10 °C. The amount of transporter-
bound radioligand was determined at different time points up to
60 min, except for the case of compounds showing a RT longer than
60 min. In this case, the total time of measurement was extended up to
180 min. The amount of transporter-bound radioligand was determined
after filtration at different time intervals and samples were obtained as
described under “Displacement experiments”.
Cmpd pIC50 (IC50
(nM))
Cmpd pIC50 (IC50
(nM))
Cmpd pIC50 (IC50
(nM))
NBTI 8.56 ± 0.03
(2.7)
3 7.28 ± 0.05
(52)
7 7.13 ± 0.08
(73)
Dilazep 8.72 ± 0.07
(1.9)
Draflazine 8.36 ± 0.08
(4.4)
8 7.58 ± 0.13
(26)
Dipyridamole 7.15 ± 0.02
(71)
4 6.62 ± 0.06
(238)
9 6.77 ± 0.07
(171)
1 6.87 ± 0.05
(135)
5 7.34 ± 0.09
(46)
2 5.26 ± 0.05
(5542)
6 7.39 ± 0.11
(40)
Wash-out experiments were performed by incubating the competing li-
gands at a final concentration of 10 × IC50 (as determined in dis-
placement experiments) with erythrocyte membranes for 1 h at 10 °C
while gently shaking. Subsequently the samples were centrifuged at
13,200 rpm (16,100 g) at 4 °C for 5 min and the supernatant containing
the unbound ligand was removed. Pellets were resuspended in 1 mL of
assay buffer, and samples were incubated for 10 min at 10 °C. The
control (unwashed) samples were kept on ice during centrifugation and
supernatant removal. After four centrifugation and washing cycles in
total, supernatant was discarded and the membranes were resuspended
in a total volume of 400 μL containing 4 nM [3H]NBTI. After 60 min
incubation at 10 °C, incubations were terminated by rapid filtration
through GF/C filters using a Brandel harvester (Brandel, Gaithersburg,
MD). Filters were washed three times and collected in tubes. Emulsifier-
Safe scintillation fluid (Perkin Elmer, Groningen, the Netherlands) was
added and samples were counted by scintillation spectrometry using a
Tri-carb 2900 TR liquid scintillation counter (Perkin Elmer, Boston,
MA).
2.5. Impedance-based morphology assay
2.5.1. Detection principle
Impedance-based morphology assays were performed using the
xCELLigence real-time cell analyser (RTCA) system [20,21], as de-
scribed previously [22]. In short, the RTCA system measures the elec-
trical impedance generated by cells adhering to gold-coated electrodes
embedded on the bottom of microelectronic E-plates. Changes in im-
pedance (Z) could result from variations in number, degree of adhesion,
cellular viability and morphology of cells. These changes are recorded
continuously at 10 kHz and displayed in the unitless parameter called
Cell Index (CI) [21,23], which is defined (Zi − Z0) Ω/15 Ω. Zi is the
impedance at a given time point and Z0 represents the baseline im-
pedance in the absence of cells, which is measured prior to the start of
the experiment.
2.5.2. Functional evaluation of pIC50 values for ENT1 inhibitors
The assay was used as previously described by Vlachodimou et al.
[24]. In short, U-2 OS cells were harvested and centrifuged at 200×g
(1500 rpm) for 5 min. Z0 was measured after the addition of 40 μL
culture media to 96 well PET E-plates (Bioké, Leiden). 20,000 cells were
A. Vlachodimou, et al. Biochemical Pharmacology 172 (2020) 113747
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added in a volume of 50 μL per well. After resting at room temperature
for at least 30 min, the E-plate was placed into the recording station
situated in a 37 °C and 5% CO2 incubator. Impedance was measured
every 15 min overnight. After 18 h of recording, cells were pre-treated
with increasing concentrations of ENT1 inhibitor or vehicle control
(0.25% DMSO in Phosphate-buffered saline (PBS)) in 5 µL. CI was re-
corded for 30 min (recording schedule: 15 s intervals for 20 min, fol-
lowed by 1 min intervals for 10 min) or 4 h (recording schedule after
30 min: 5 min interval for 45 min, followed by 15 min intervals).
Subsequently, cells were stimulated with 10−4.5 M adenosine or vehicle
control (0.125% DMSO in PBS) in 5 μL and CI was recorded for at least
90 min with a recording schedule of 15 s intervals for 20 min, followed
by intervals of 1 min for 10 min and finally 5 min. In all cases, final well
volumes and DMSO concentrations upon cell and ligands addition were
100 μL and 0.375%, respectively, for all wells.
2.6. Data analysis
2.6.1. Radioligand binding assays
Data analyses were performed using GraphPad Prism 8.1 software
(GraphPad Software Inc., San Diego, CA, USA). KD and Bmax values were
obtained from radioligand saturation assays by non-linear regression
curve fitting using the one site: “total and non-specific binding” equa-
tion. pIC50 values were obtained from radioligand displacement assays
by non-linear regression curve fitting into a sigmoidal concentration-
response curve using the “log(inhibitor) vs. response” graphpad ana-
lysis equation. The data were fitted both in “log(inhibitor) vs. response
(three parameters)” and “log(inhibitor) vs. response – Variable slope
(four parameters)”, and the two analysis were compared. In all cases
the former analysis was preferred where the Hill-slope is fixed at −1.0,
showing competitive binding. Hence, pKi values were calculated from
pIC50 values and the saturation KD value via the Cheng-Prusoff equation
[25]: Ki = IC50/(1 + [radioligand]/KD).
The dissociation rate constant koff was obtained using a one-phase
exponential decay analysis of data from a radioligand dissociation
assay. Association rate constant kon was determined using the equation:
kon = (kobs − koff)/[radioligand], in which L is the concentration of
radioligand and kobs was determined using a one phase association
analysis of data from a radioligand association assay. The association
and dissociation rates were used to calculate the kinetic KD using:
KD = koff/kon.
Association and dissociation rate constants for unlabelled ENT1
inhibitors were determined by non-linear regression analysis of com-
petition association data as described by Motulsky and Mahan [26]. The
kinetics of competitive binding analysis of GraphPad Prism software
was used, where k1 and k2 are the kon (M−1min−1) and koff (min−1) of
[3H]NBTI obtained from radioligand association and dissociation as-
says, respectively, L is the radioligand concentration (nM), I is the
concentration of unlabeled competitor (nM), X is the time (min) and Y
is the specific binding of the radioligand (DPM). Fixing these para-
meters allows the following parameters to be calculated: k3, which is
the kon value (M−1min−1) of the unlabeled ligand; k4, which is the koff
value (min−1) of the unlabeled ligand and Bmax, that equals the total
binding (DPM). All competition association data were globally fitted.
The residence time (RT) was calculated using: RT = 1/koff [27].
cLogP values were calculated using ChemDraw Professional 16.0.
All data are shown as mean ± S.E.M. of at least three independent
experiments performed in duplicate. Statistical analysis was performed
if indicated, using a parametric paired Student’s t test (ns p > 0.05, *
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001).
2.6.2. Label-free whole-cell assay
RTCA software 2.0 (ACEA Biosciences, Inc.) was used to capture the
experimental data. All data were analyzed using GraphPad Prism 8.1
(GraphPad software, San Diego, CA, USA). Ligand responses, baseline-
corrected to vehicle control, were normalized at the time of ligand
addition to obtain Δ Cell Index (Δ CI) values to correct for ligand-in-
dependent responses. The time of normalization was either at ap-
proximately 18 h 30 min or at 22 h after cell seeding for analysis of
adenosine effect (depending on the pre-incubation time of the in-
hibitors, i.e. 30 min or 4 h).
The absolute values of Total Area Under the Curve (AUC) up to
Fig. 2. Characterization of [3H]NBTI binding to hENT1 transporters endogenously expressed on erythrocyte membranes at 10 °C. (A) Saturation analysis of [3H]NBTI
binding. (B) Association and dissociation kinetics of 4 nM [3H]NBTI to and from hENT1 transporters. Data are expressed as percentage of specific [3H]NBTI binding.
(C) Competition association assay of [3H]NBTI (4 nM) in the absence or presence of 0.3×, 1×, and 3× IC50 of unlabeled NBTI. (D) Displacement of [3H]NBTI (4 nM)
from hENT1 by non-labeled NBTI, dilazep, dipyridamole and draflazine. Data are shown as mean ± SEM from at least three independent experiments performed in
duplicate.
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90 min after adenosine addition were exported to Graphpad Prism for
further analysis yielding concentration–response curves. pIC50 values of
ENT1 inhibitors (Table 3) were obtained using non-linear regression
curve fitting of Total AUC data into a sigmoidal dose–response curve as
described by “log(inhibitor) vs. response (three parameters)” analysis of
graphpad prism software. Data shown are the mean ± SEM of at least
three individual experiments performed in duplicate.
3. Results
3.1. Characterization of [3H]NBTI binding
The affinity of [3H]NBTI for the hENT1 transporter on erythrocyte
membranes was determined with saturation binding experiments
(Fig. 2A). Transporter binding was saturable and characterized by a KD
of 1.1 nM and a Bmax of 31 pmol/mg (Table 1). In addition, homologous
displacement experiments with [3H]NBTI resulted in a pKi value of 9.24
for NBTI (Fig. 2D, Table 1).
Next to equilibrium radioligand binding assays, kinetic binding as-
says were performed to establish the association (kon) and dissociation
(koff) rate constants of [3H]NBTI for the hENT1 transporter expressed on
erythrocyte membranes (Fig. 2B, Table 1). Equilibrium binding was
reached in less than 15 min, while complete dissociation was reached
within 150 min, as assessed by association and dissociation experiments
best fitted with a one-phase model. As a result, kon, koff and RT values of
0.08 nM−1 min−1, 0.036 min−1 and 28 min were calculated, respec-
tively. From the aforementioned kinetic data the dissociation constant
(kinetic KD) was calculated and found to be 0.45 nM, which together
with the equilibrium KD obtained from saturation binding experiments
indicated high affinity binding of [3H]NBTI for the hENT1 transporter.
3.2. Determination of the binding affinity of hENT1 inhibitors
Radioligand binding studies of 13 inhibitors were performed to
determine their equilibrium binding affinity for the ENT1 transporter.
All ligands were able to inhibit specific [3H]NBTI binding to ENT1
completely, in a competitive and concentration-dependent manner. The
reference marketed compounds displayed high affinities, with Ki values
of 0.41 nM for dilazep and 14 nM for dipyridamole (Table 2). In con-
trast, draflazine and its analogues presented a greater range of affi-
nities, ranging from 0.94 nM to 1133 nM for draflazine and compound
2, respectively (Table 2).
3.3. Validation and optimization of the competition association assay
In order to determine the binding kinetics of all non-radiolabeled
ligands of interest, a radioligand competition association assay was set
up. The specific binding of radiolabeled NBTI was measured over a time
course of 60 min, in the absence and presence of three different con-
centrations of unlabeled NBTI, i.e. 0.3, 1.0 and 3.0-fold its IC50 value as
determined from the displacement assays (Fig. 2C). By fitting the kon
and koff values of [3H]NBTI binding into the “kinetics of competitive
binding” model as described in the Materials and Methods section, the
kon and koff values of the unlabeled NBTI were calculated to be
0.114 nM−1 min−1 and 0.051 min−1, respectively (Table 1). As the kon
and koff values obtained from this assay were in very good agreement
with those from the classical association and dissociation assays, the
competition association assay was deemed validated for determining
unlabeled ligand’s binding kinetics. Subsequently, a single concentra-
tion of NBTI (1.0-fold its IC50) was assessed and found to result in si-
milar binding kinetic values, i.e. 0.104 ± 0.014 nM−1 min−1 and
0.045 ± 0.001 min−1 for kon and koff respectively (data not shown).
Consequently, the throughput of this competition association assay was
increased, and it was decided to test other ligands at a concentration
equal to 1.0-fold their IC50 only.
3.4. Determination of the binding kinetics of unlabeled hENT1 inhibitors
All the ligands with affinity values lower than 100 nM were eval-
uated in the competition association assay in order to determine their
binding kinetic parameters, kon, koff, RT and KD. Fig. 3A presents the
curves of the reference inhibitors dilazep and dipyridamole, which
display similar, and shorter RTs compared to the radioligand [3H]NBTI
(control curve), respectively. In Fig. 3B, the graph obtained with dra-
flazine and the long RT compound 4 is presented, where the incubation
was increased to 3 h as their residence time exceeded that of the
radioligand. This resulted in a characteristic overshoot followed by a
steady decrease to a lower equilibrium. Association rate constants of all
ligands displayed a modest 8-fold range, i.e. 0.0016 nM−1 min−1 for
compound 4 to 0.013 nM−1 min−1 for 1 and 6. In contrast, dissociation
rate constants exhibited a greater 101-fold range, with compounds 4
and 1 having the lowest and the highest values (0.0016 min−1 and
0.162 min−1), respectively.
3.5. Structure-affinity relationships (SAR) and structure-kinetic
relationships (SKR) of draflazine analogues
In an effort to better compare the inhibitors tested and understand
their interactions with the transporter, both SAR and SKR were drawn
based on the affinities (Ki values) and the kinetic parameters (kon, koff
values and RT), obtained from the equilibrium binding and competition
association assays. Amongst the reference compounds, i.e. NBTI, di-
lazep, dipyridamole and draflazine, only draflazine presented a longer
RT (Tables 1 and 2). Thus, the draflazine scaffold was selected for
further binding kinetic characterization. To efficiently explore the SAR
and SKR around the draflazine scaffold, nine draflazine analogues, with
variation in the length of the carbon linker connecting the the piper-
azine and the (bis)fluorophenyl moieties, the position and type of
substitution on the piperazine ring, and substituent on the 4-position of
the 2,6 di-chloro phenyl ring were studied for their affinity. From these
Table 1
Comparison of the affinity, dissociation constants and kinetic parameters of reference ENT1 inhibitor, NBTI, obtained with different radioligand binding assays
performed on human erythrocyte membranes.
Assay Bmax
(pmol/mg)
KD (nM) pKi
(Ki (nM))a
kon
(nM−1 min−1)
koff
(min−1)
RT
(min)
Saturation binding 31 ± 0.9 1.1 ± 0.028 – – – –
Displacement – – 9.24 ± 0.03
(0.57)
– – –
Association and dissociation – 0.45 ± 0.05b – 0.080 ± 0.007 0.036 ± 0.002 28 ± 1.4
Competition association – 0.45 ± 0.06b – 0.114 ± 0.014c 0.051 ± 0.003c 20 ± 1.3c
Values are mean ± SEM of at least three individual experiments performed in duplicate.
a pKi values were calculated from pIC50 values and the saturation KD value using the Cheng-Prusoff equation: Ki = IC50/(1 + [radioligand]/KD).
b Kinetic KD values determined by association and dissociation, and competition association assay, is defined as KD = koff//kon.
c The binding kinetics of unlabeled NBTI were determined by addition of 0.3-, 1- and 3-fold its IC50 value (as obtained from displacement assays).
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analogues, only eight showed sufficient affinity to warrant further
characterization of their binding kinetics.
Compound 1 was taken as the starting point. Replacement of car-
boxamide at the R2 with an methylamide (2) led to a decreased affinity.
As a result, carboxamide was used as the R2 substituent for compounds
3–5 and draflazine. Increasing the carbon chain length by 1 carbon
(m = 1; 3) resulted in a moderate increase in affinity and a decrease in
dissociation rate constant. Introducing an amine on the R3 position
(draflazine) increased the affinity, resulting in the highest affinity for
hENT1 of all measured compounds. In addition, a modest increase in
kon and a 2-fold decrease in koff was presented, yielding in an inter-
mediate RT of 88 min. The SAR and SKR study continued with the di-
Table 2
Affinity (pKi, KD) and kinetic parameters (kon, koff, RT) of reference ENT1 inhibitors and inhibitors 1–9, sharing the draflazine scaffold.
Cmpd m R1 R2 R3 pKi
(Ki (nM))a
kon
(nM−1min−1)
koff
(min−1)
RT
(min)b
KD
(nM)c
Dilazep – – – – 9.39 ± 0.06
(0.41)
0.10 ± 0.00 0.023 ± 0.004 44 ± 7.6 0.22 ± 0.04
Dipyridamole – – – – 7.85 ± 0.04
(14)
0.008 ± 0.001 0.082 ± 0.003 12 ± 0.5 10 ± 1.3
1 0 H CONH2 H 7.56 ± 0.05
(28)
0.013 ± 0.003 0.16 ± 0.04 6.2 ± 1.5 13 ± 4.7
2 0 H CONHCH3 H 5.95 ± 0.05
(1133)
n.d.d n.d. n.d. n.d.
3 1 H CONH2 H 7.98 ± 0.05
(10)
0.009 ± 0.000 0.022 ± 0.001 46 ± 2.9 2.5 ± 0.2
Draflazine* 1 H CONH2 NH2 9.03 ± 0.08
(0.94)
0.010 ± 0.004 0.011 ± 0.004 88 ± 30 1.1 ± 0.6
4 1 H CONH2 N(CH3)2 7.33 ± 0.06
(47)
0.0016 ± 0.0002 0.0016 ± 0.0007 628 ± 294 1.0 ± 0.5
5 1 H CONH2 COCH3 8.05 ± 0.08
(8.9)
0.007 ± 0.002 0.012 ± 0.001 83 ± 6.2 1.6 ± 0.4
6 0 CONH2 H H 8.09 ± 0.11
(8.2)
0.013 ± 0.002 0.055 ± 0.004 18 ± 1.3 4.2 ± 0.6
7 0 CONHCH3 H H 7.82 ± 0.09
(15)
0.004 ± 0.000 0.051 ± 0.002 20 ± 0.8 12 ± 0.8
8 1 CONH2 H H 8.27 ± 0.12
(5.4)
0.009 ± 0.001 0.014 ± 0.001 71 ± 5.1 1.6 ± 0.2
9 1 CONH2 H N(CH3)2 7.46 ± 0.05
(34)
0.003 ± 0.000 0.022 ± 0.003 46 ± 6.2 8.2 ± 1.7
Values represent the mean ± SEM of at least three individual experiments, performed in duplicate.
a pKi values were calculated from pIC50 values and the saturation KD value using the Cheng-Prusoff equation: Ki = IC50/(1 + [radioligand]/KD).
b RT = 1/koff.
c Kinetic KD values, defined as KD = koff//kon.
d n.d. = not determined.
* Draflazine is the (−)-enantiomer, as shown in Fig. 1.
Table 3
Potency (pIC50) of ENT1 inhibitors draflazine and compound 4, determined by
functional assay.
pIC50 (IC50 (nM))
30 min pre 4 h pre
Draflazine 8.28 ± 0.04
(5.31)
8.54 ± 0.14
(2.87)
Compound 4 7.25 ± 0.06
(56.6)
8.38 ± 0.17
(4.16)
Values represent the mean ± SEM of at least three individual experiments,
performed in duplicate.
Fig. 3. Evaluation of binding kinetics of reference compounds and the longest RT draflazine analogue at 10 °C. The assays have been performed on erythrocyte
membranes with 4 nM of [3H]NBTI. (A) Competition association assay of [3H]NBTI to hENT1 transporter in the absence or presence of IC50 concentration of the
reference ENT1 inhibitors dilazep and dipyridamole. (B) Competition association assay of [3H]NBTI to hENT1 transporter in the absence or presence of an IC50
concentration of draflazine and compound 4. The duration of the measurement was increased to 3 h in order to more accurately assess compound 4’s long RT. (C)
Recovery of radioligand binding after washing. [3H]NBTI binding after 1 h pre-incubation with a 10 × IC50 concentration of ENT1 inhibitors followed by no
(unwashed) or 4× (washed) washing. Data are shown as mean ± SEM from at least three independent experiments performed in duplicate. Statistical analysis
between the unwashed and washed condition of each ligand were performed using parametric paired t-tests. ns p > 0.05, ** p ≤ 0.01, **** p ≤ 0.0001.
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substitution of the amine with methyl which led to compound 4.
Compound 4 showed a significantly lower affinity (50-fold) for ENT1
compared to draflazine, as well as a 6-fold and 7-fold decrease in kon
and koff, respectively. However, due to the slow dissociation rate of
compound 4, no equilibrium was reached in this 60 min assay. As a
consequence the derived pKi value is an underestimated apparent af-
finity. Compound 4’s kinetic affinity KD is therefore a better parameter,
and no decrease of affinity was observed compared to draflazine.
Compound 4 proved to be the longest RT (> 10 h) compound tested,
while showing the lowest association rate constant. Subsequently, the
introduction of an acetyl group (5) was investigated. Compared to
draflazine, compound 5 showed a decrease in affinity of half a log unit,
while no change was observed for RT strong decrease in RT, resulting in
an intermediate RT of 83 min.
In addition to substitution of the R2 position of the piperazine, the
R1 position was investigated. Compounds 6, 7, 8 and 9 were in-
vestigated as counterparts to 1,2,3 and 4 and the same trend was ob-
served. In all cases, a linker of 4 carbons (m = 1; 8 and 9) and an
carboxamide (6, 8 and 9) instead of methylamide (7) resulted in higher
affinities. Furthermore, by comparison of 1 and 6, 3 and 8, 4 and 9, it is
not clear if substitution with carboxamide on the R1 or R2 position of
the piperazine moiety is crucial for longer RT. The study of draflazine, 4
and 9 reveals that para-substitution of the 2,6 di-chloro phenyl ring
with an amine increased the RT.
3.6. Evaluation of binding kinetics in a washout assay
To further validate the findings of the competition association assay,
a washout radioligand binding assay was developed as described under
Section 2. In this assay the recovery of radioligand binding before and
after several wash-centrifugation steps by incubation with NBTI, di-
lazep, dipyridamole and compound 4 with the transporter was in-
vestigated. Dipyridamole showed a complete recovery in radioligand
binding after the wash-centrifugation steps, while for NBTI and dilazep
a partial recovery was found (Fig. 3C), indicating that these inhibitors
were either entirely or partially washed from the transporter. On the
contrary, pre-incubation with compound 4 completely prevented a re-
covery of radioligand binding, as no significant difference was observed
between the washed and unwashed condition (0.94% and 0.15%, re-
spectively, Fig. 3C). Notably, in all cases the level of radioligand
binding recovery was in agreement with the data from the competition
association assay, i.e. the longer the RT time of the compounds tested,
the smaller the recovery in radioligand binding measured after the
washing steps (i.e. compound 4 < dilazep < NBTI < dipyridamole
in both cases).
3.7. Kinetic map and correlation plots
Next, we represented all compounds in a kinetic map to better il-
lustrate the added value of determining structure-kinetic relationships
(SKR), next to studying traditional structure-affinity-relationships
(SAR) (Fig. 4). In this map, the association (x-axis) and dissociation (y-
axis) rate constants are plotted resulting in the kinetic affinity on the
diagonal axis. As can be observed from this plot, two compounds on the
same diagonal line have the same affinity for ENT1, but can have
various combinations of association and dissociation rate constants. For
example, compound 4 and NBTI have similar kinetic affinities (1.0 and
0.45 nM, respectively), however their kon and koff values differ by 71-
and 32-fold, respectively. Furthermore, compounds may have an equal
RT on ENT1, yet their affinity and association rates can differ a lot (e.g.
NBTI and compound 7 have a RT of 20 min, while their affinity and kon
vary by 27- and 29-fold, respectively). Lastly, inhibitors could exhibit
similar association rate constants, but different affinities due to di-
vergent dissociation rate constants, like draflazine and compound 1.
In order to get a better insight into the relationship between the
different parameters obtained in this study, correlation plots were
constructed (Fig. 5). The affinity obtained from equilibrium radioligand
binding assays (pKi) for all compounds was plotted against the affinity
calculated from the kinetic parameters (pKD) and found to have a
modest, yet significant correlation (r = 0.75, p = 0.0048). However,
when the long RT compound (4; depicted by a red square in Fig. 5A)
was excluded, the two parameters were highly correlated (r = 0.92,
p < 0.0001), suggesting that valid affinity values are best obtained
through kinetic assays. Secondly, the association (logkon) and dis-
sociation (pkoff) rate constants of all draflazine analogues were plotted
against their kinetic affinity (pKD) (Fig. 4B, 4C). Here, only the pkoff was
strongly correlated with kinetic affinity (r = 0.83, p = 0.0057), while
this correlation was not observed with the equilibrium affinity
(r = 0.61 and p = 0.084 for logkon vs pKi, r = 0.01 and p = 0.98 for
pkoff vs pKi; data not shown). Lastly, the lipophility (clogP) of all dra-
flazine analogues was calculated, and it was not found to be sig-
nificantly correlated with pKD (r = −0.075, p = 0.85), logkon
(r = −0.56, p = 0.09) (Fig. 4D, 4E) or pkoff (r = 0.51, p = 0.13; data
not shown).
3.8. Functional evaluation of binding kinetics for draflazine and compound
4
Finally, the large difference in RT of reference compound draflazine
and its analogue 4, and therefore the affinities established by 1 h
equilibrium (pKi) or kinetic (KD) radioligand binding assays, prompted
us to investigate time-dependence in a functional assay. In short, in-
creasing concentrations of the inhibitors were pre-incubated with U-2
OS cells for 30 min (Fig. 6A, B) or 4 h (Fig. 6C, D), followed by a 90 min
incubation with 10-4.5 M adenosine. The latter induces activation of
adenosine receptors, without which the effects of the ENT1 inhibitors
cannot be observed. The area under the curve (AUC) of adenosine
signaling was measured and found to be concentration-dependent for
both inhibitors. Interestingly, the presence of compound 4 resulted in a
left-ward shift of the adenosine effect with a longer pre-incubation
time, while a small, if any, difference was observed with longer pre-
incubation of draflazine (Fig. 6E, F). As detailed in Table 3, the in-
hibitory effect of draflazine was slightly affected, yielding in an ap-
proximate 2-fold shift in IC50 value, while the potency of compound 4
was increased by about 47-fold. This suggests that an inhibitor with
longer transporter residence time has an increased level of target oc-
cupancy over time, resulting in a higher potency.
Fig. 4. Kinetic map of all kinetically characterized inhibitors. The kinetically
derived affinity (KD) is represented by the diagonal parallel lines. The names/
numbers of a few compounds are indicated in red next to the corresponding
data point. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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4. Discussion
Affinity and potency have been and currently still are the main
parameters investigated during in vitro drug discovery programs.
However, during the last decade the importance of ligand binding ki-
netics has been highlighted by several studies [13,16]. The determi-
nation of the association and dissociation rate constant of a ligand to
and from its target, in addition to residence time, has become the topic
of many studies for various targets, such as G protein-coupled receptors
(GPCRs) [28], kinases [29], ion channels [30] and other proteins [31].
In order to better understand the mechanism of action of ENT1 in-
hibitors, and to develop novel ones, it is essential to examine their
binding kinetic parameters too [32]. Hence, in this study we focused on
determining the affinity and binding kinetic parameters of reference
ENT1 inhibitors including draflazine, as well as a number of draflazine
analogues.
A radioligand binding assay was used to determine the equilibrium
affinity of all inhibitors. The affinities reported in our study are in line
with the literature reports, where the affinity and/or the anti-ag-
gregation effect of the reference compounds (NBTI, dilazep, dipyr-
idamole and draflazine) [18,33,34] and compounds 1, 3, 5, 6 and 9
[35–37]. Moreover, we found that for all inhibitors a Hill slope of −1
was preferred, indicating that the ligands are competing for the same
binding site as [3H]NBTI. This finding is substantiated by the recently
published crystal structure of ENT1 that indicates a commonly shared
orthosteric binding site for NBTI and dilazep [7]. This binding site is
then probably also targeted by dipyridamole, draflazine and its analo-
gues.
The binding kinetics of the ENT1 inhibitors were evaluated with a
competition association assay, which is based on the Motulsky-Mahan
model that determines the time-dependent binding of two competing
ligands [26]. As draflazine showed the longest RT of the reference ENT1
inhibitors, the draflazine scaffold was selected for further investigation
of binding kinetic parameters (Tables 1 and 2). The association rate
constants of the investigated analogues showed a small range of about
one log unit, making correlations feeble. However, association rate
constants should not be overlooked during drug optimization, when
taking the disease of interest into consideration. For an acute disease, a
fast association is required as an immediate response is vital [38]. In
case of a chronic disease, koff may seem of higher importance due to the
long lasting effect needed, yet kon is also of essence as the drug may
need to compete with high concentrations of endogenous ligand under
pathophysiological conditions [15]. In this study, we found that koff and
thus RT of the examined compounds ranged over two log units, from
6.2 min (1) up to 628 min (compound 4), while their affinities were less
divergent (Table 2). This broad range in koff values is of interest when
the concept of kinetic selectivity is also taken into account. As reviewed
by Tonge [16], compounds with similar pKi affinities for multiple tar-
gets (absence of thermodynamic selectivity) could still demonstrate
kinetic selectivity for a target, which has been shown for muscarinic M3
receptors [39,40], LpxC enzyme [41] and cyclin-dependent kinases 2
and 9 [42]. Although dilazep and dipyridamole are marketed drugs
targeting ENT1, they are known to bind multiple targets, such as ENT2
[43] and phosphodiesterases (PDE) 5, 6, 8, 10, 11 [44]. As a result, a
compound with high affinity and a long RT, such as the draflazine
analogue compound 4 deserves further investigation. Actually,
Fig. 5. Correlation plots between affinity, kinetic parameters and lipophilicity. (A) Affinity determined from equilibrium displacement assays (pKi) of all compound
tested versus their kinetic affinity (pKD) determined based on association (kon) and dissociation (koff) rate constants obtained from competition association assays. (B)
Kinetic affinity (pKD) of all draflazine analogues plotted against their association rate constants (logkon), or (C) dissociation rate constants (pkoff). (D) Lipophility
(cLogP values) of all draflazine analogues plotted against their kinetic affinity, or (E) association rate constants. The solid line corresponds to the linear regression of
the data, the dotted line represents the 95% confidence interval for regression and the Pearson r coefficient is shown. Data used in the plots are detailed in Tables 1
and 2. Data are expressed as mean from at least three independent experiments performed in duplicate.
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draflazine itself might for that reason be of less interest, although it was
heavily investigated in clinical studies for unstable coronary disease
[45] and in vivo animal studies on ischemic arrhythmias [46], for ex-
ample.
Investigation of the correlations between equilibrium (pKi) and ki-
netic (pKD) affinity (Fig. 5A) revealed a weak correlation between the
two parameters. Only once the long RT inhibitor (4) was excluded, the
two parameters were well correlated. Excluding compound 4 was
supported by the fact that the equilibrium affinity, pKi, was determined
during a one hour assay, in which compounds with long RT had not yet
reached equilibrium (Table 2, Fig. 3B), resulting in the measurement of
an apparent and underestimated affinity. In addition, examination of
binding kinetic parameters along with the “real” kinetic affinity re-
vealed that affinity for the compounds of this study on ENT1 is driven
by the dissociation rate constant (Fig. 5B, C). In the past years, corre-
lations have been performed between binding kinetic parameters and
affinity in many studies and for multiple targets, like GPCRs and ion
channels. In the case of neurokinin 1 (NK1) receptor, both dissociation
and association rates of endogenous agonists correlated well with affi-
nity [32], while for the binding to metabotropic glutamate 2 (mGlu2)
receptor or to Kv11.1 ion channel, only the kon was the determinant
parameter for affinity [30,47]. When the cannabinoid receptor type-2
(CB2) agonists where investigated, only the koff was driving force for
affinity [48]. From the plethora of data available, it has been shown
that these correlations are target-specific and therefore could not have
been hypothesized in advance [49].
Furthermore, washout radioligand experiments were performed to
provide further insight in the binding kinetics and validate that the
determined RT for compound 4 is a result of a long-lasting complex of
the compound with the transporter and not of rebinding. The latter
phenomenon is described as the renewed binding of recently dis-
sociated ligands originating from the local environment of the target
[16,50]. These high concentrations in the micro-environment could
result in a long “overall”/apparent RT of a compound by consecutive
binding to its initial target or those nearby [51]. However, the persis-
tent binding of ENT1 by compound 4 after intensive washout, hence
removal of the free inhibitor from the system, supports that the long-
lasting complex of the compound with the transporter is due to long RT
and not rebinding.
Next to binding parameters, the potency of selected inhibitors was
studied, in order to investigate any possible correlation between
binding kinetic parameters and functional efficacy. Here we used a
recently developed real-time label-free assay to study ENT1 inhibition
[24]. This assay is an indirect functional assay that measures the
changes in adenosine receptor signaling resulting from ENT1 inhibition.
In short, U-2 OS cells, endogenously expresses ENT1 and adenosine
receptors (mainly A2B) were pre-treated with the ENT1 inhibitors and
subsequently treated with adenosine. In case of a potent inhibitor, high
levels of ENT1 inhibition would be achieved, resulting in a significantly
elevated extracellular concentration of adenosine, hence increased
adenosine receptor signaling. Likewise, a weak ENT1 inhibitor would
allow the translocation of adenosine intracellularly, leading to a lower
extracellular concentration of adenosine and thus less adenosine re-
ceptor signaling. Thus, this assay simulates the physiologically relevant
outcome of ENT1 inhibition, i.e. the modulation of the extracellular
concentration of adenosine. As NBTI, dilazep and dipyridamole have
been studied previously in this assay [24], we here examined the po-
tency of a fourth reference inhibitor, draflazine, and its longest RT
analogue, compound 4 (Table 2). A time-dependent effect was observed
for the long RT inhibitor compound 4, as its potency increased after a
Fig. 6. Functional characterization of draflazine and compound 4 on hENT1 endogenously expressed on U-2 OS cells. Cells were pre-incubated for 30 min or 4 h and
subsequently stimulated with 10−4.5 M adenosine. Concentration-dependent effects of draflazine (A,C) and compound 4 (B, D) after 30 min (A, B) and 4 h (C, D) of
pre-incubation, where representative xCELLigence traces of baseline-corrected adenosine responses are shown. Concentration-response curves of draflazine (E) and
compound 4 (F) derived from corresponding AUCs up to 90 min after adenosine addition. Data shown are mean ± SEM from at least three separate experiments
performed in duplicate.
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longer pre-incubation with the transporter (Table 3 and Fig. 4). Taken
together, the shift in potency of compound 4 indicates that ligand
binding kinetics is a good predictor of in vivo target occupancy. Note-
worthy, a typically used 30 min pre-incubation time with the inhibitors
resulted in IC50 values (Table 3) that were similar to the pKi values
determined by equilibrium radioligand binding assays (Table 2), while
4 h pre-incubation resulted in IC50 values similar to the “real” affinities
calculated based on the kinetic characteristics (KD) of the compounds
(Table 2). In other words, by not taking the kinetic aspects of ligand-
target binding of long RT compounds into account (either by per-
forming kinetic binding assays or by increasing incubation times in
functional assays), the resulting (improved) pharmacological effect will
be missed. Thus, the study of binding kinetics during a drug discovery
project is of essence. Nevertheless, there are multiple pharmacological
parameters that contribute to a pharmacological and safety profile of a
drug. Therefore in addition to affinity, potency and binding kinetics,
other parameters such as bioavailability, toxicity, metabolism and
pharmacokinetic clearance should still be investigated.
In conclusion, we have established and validated a competition
association assay as a valuable tool to determine the binding kinetics of
unlabeled ENT1 inhibitors. Four reference inhibitors for ENT1 were
characterized for their affinity and binding kinetics, while 9 analogues
of draflazine were kinetically profiled for the first time. koff Values were
shown to be correlated to affinity, revealing that target engagement of
ENT1 inhibitors is governed by their dissociation rate constants. The
study of two compounds with distinct binding kinetics in a non-equi-
librium functional assay demonstrated that a longer target-inhibitor
complex is correlated to an increased functional effect, underlining an
increased target occupancy for long RT inhibitors.
All in all, this is the first study where SKR are drawn in addition to
SAR for ENT1 inhibitors, and relate inhibitors’ binding kinetics to their
functional effect. Hence, this study may inspire the incorporation of
binding kinetics in the research and development of ENT1 inhibitors
and likewise for other transport proteins.
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